While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

Chong EA, Ruella M, Schuster SJ. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med. 2021;384(7):673–4. Raj SS, Fei T, Fried S, et al. An inflammatory biomarker ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

A novel autologous CAR-T therapy, YTB323, with preserved t-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov 2023;13:1982-1997. Crossref ...

Breyanzi is a CAR T therapy for various forms of non-Hodgkin lymphoma. “Breyanzi has demonstrated efficacy and manageable safety in five cancer types, the most of any CD19-directed CAR T-cell ...

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...

Dual-target CAR. CAR T cell therapy is a form of personalized immunotherapy that uses a patient's own immune cells to treat their cancer. While widely successful in blood cancers, CAR T cell ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...

CAR-T cell therapy is often impractical for patients needing second-line therapy, according to a presentation from the 2025 CURE Educated Patient® Multiple Myeloma Summit. “CAR-T cell therapy refers ...

Citation: Successful CAR-T cell therapy for end-stage multiple myeloma using advanced cellular product performed in Hong Kong (2025, March 27) retrieved 15 July 2025 from https://medicalxpress.com ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. The findings, led by researchers in the Perelman ...